Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease

Brain - Tập 131 Số 6 - Trang 1630-1645 - 2008
Miloš D. Ikonomović1, William E. Klunk1, Eric E. Abrahamson1, Chester A. Mathis1, Julie C. Price1, Nicholas D. Tsopelas1, Brian J. Lopresti1, Scott K. Ziolko1, Wenzhu Bi1, William R. Paljug1, Manik L. Debnath1, Caroline E. Hope1, Barbara A. Isanski1, Ronald L. Hamilton1, Steven T. DeKosky1
1Department of Neurology, 2Department of Psychiatry, 3Department of Radiology and 4Department of Neuropathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

Consensus report of the Working Group on “Molecular and Biochemical Markers of Alzheimer's Disease”, 1998, The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group, Neurobiol Aging, 19, 109

Bacskai, 2007, Molecular imaging with PiB confirmed at autopsy: a case report, Arch Neurol, 64, 431, 10.1001/archneur.64.3.431

Braak, 1991, Neuropathological stageing of Alzheimer-related changes, Acta Neuropath, 82, 239, 10.1007/BF00308809

Braak, 1991, Neuropathological staging of Alzheimer's disease, Acta Neuropath, 82, 239, 10.1007/BF00308809

DeKosky, 2007, Association of increased cortical soluble abeta42 levels with diffuse plaques after severe brain injury in humans, Arch Neurol, 64, 541, 10.1001/archneur.64.4.541

Engler, 2006, Two-year follow-up of amyloid deposition in patients with Alzheimer's disease, Brain, 129, 2856, 10.1093/brain/awl178

Fodero-Tavoletti, 2007, In vitro characterization of Pittsburgh compound-B binding to Lewy bodies, J Neurosci, 27, 10365, 10.1523/JNEUROSCI.0630-07.2007

Forsberg, 2007, PET imaging of amyloid deposition in patients with mild cognitive impairment, Neurobiol Aging

Gauthier, 2006, Mild cognitive impairment, Lancet, 367, 1262, 10.1016/S0140-6736(06)68542-5

Growdon, 1999, Biomarkers of Alzheimer disease, Arch Neurol, 56, 281, 10.1001/archneur.56.3.281

Grundke-Iqbal, 1989, Amyloid protein and neurofibrillary tangles coexist in the same neuron in Alzheimer disease, Proc Natl Acad Sci USA, 86, 2853, 10.1073/pnas.86.8.2853

Guntern, 1992, An improved thioflavine-S method for staining neurofibrillary tangles and senile plaques in Alzheimer's disease, Experientia, 48, 8, 10.1007/BF01923594

Harigaya, 2000, Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain, Biochem Biophys Res Commun, 276, 422, 10.1006/bbrc.2000.3490

Hyman, 1992, Kunitz protease inhibitor-containing amyloid beta protein precursor immunoreactivity in Alzheimer's disease, J Neuropathol Exp Neurol, 51, 76, 10.1097/00005072-199201000-00009

Hyman, 1989, A4 amyloid protein immunoreactivity is present in Alzheimer's disease neurofibrillary tangles, Neurosci Lett, 101, 352, 10.1016/0304-3940(89)90559-4

Ikonomovic, 2006, X-34, a histofluorescent marker of abnormal protein aggregates with amyloid structure, in neuropathological studies of preclinical and clinical Alzheimer's disease, Methods Enzymol, 412, 123, 10.1016/S0076-6879(06)12009-1

Iwatsubo, 1994, Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43), Neuron, 13, 45, 10.1016/0896-6273(94)90458-8

Johnson, 2007, Imaging of amyloid burden and distribution in cerebral amyloid angiopathy, Ann Neurol, 62, 229, 10.1002/ana.21164

Kamal, 2001, Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP, Nature, 414, 643, 10.1038/414643a

Kemppainen, 2007, PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment, Neurology, 68, 1603, 10.1212/01.wnl.0000260969.94695.56

Khachaturian, 1985, Diagnosis of Alzheimer's disease, Arch Neurol, 42, 1097, 10.1001/archneur.1985.04060100083029

Kim, 1990, Detection and quantification of β-peptide with two monoclonal antibodies, Neurosci Res Commun, 7, 113

Kitamoto, 1987, Formic acid pretreatment enhances immunostaining of cerebral and systemic amyloids, Lab Invest, 57, 230

Klunk, 1998, Biological markers of Alzheimer's disease, Neurobiol Aging, 19, 145, 10.1016/S0197-4580(98)00013-X

Klunk, 2003, Imaging the pathology of Alzheimer's disease: amyloid imaging with positron emission tomography, Neuroimaging Clin N Am, 13, 781, 10.1016/S1052-5149(03)00092-3

Klunk, 2004, Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B, Ann Neurol, 55, 306, 10.1002/ana.20009

Klunk, 2005, Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain, J Neurosci, 25, 10598, 10.1523/JNEUROSCI.2990-05.2005

Klunk, 2001, Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain, Life Sci, 69, 1471, 10.1016/S0024-3205(01)01232-2

Klunk, 2003, The binding of BTA-1 to post-mortem brain homogenates is dominated by amyloid component, J Neurosci, 23, 2086, 10.1523/JNEUROSCI.23-06-02086.2003

Lalowski, 1996, The “nonamyloidogenic” p3 fragment (amyloid beta17-42) is a major constituent of Down's syndrome cerebellar preamyloid, J Biol Chem, 271, 33623, 10.1074/jbc.271.52.33623

Lammertsma, 1996, Simplified reference tissue model for PET receptor studies, Neuroimage, 4, 153, 10.1006/nimg.1996.0066

Lockhart, 2007, PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis, Brain, 130, 2607, 10.1093/brain/awm191

Logan, 1996, Distribution volume ratios without blood sampling from graphical analysis of PET data, J Cereb Blood Flow Metab, 16, 834, 10.1097/00004647-199609000-00008

Lopez, 2000, Research evaluation and diagnosis of possible Alzheimer's disease over the last two decades: II, Neurology, 55, 1863, 10.1212/WNL.55.12.1863

Lopez, 2000, Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades: I, Neurology, 55, 1854, 10.1212/WNL.55.12.1854

Lopresti, 2005, Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis, J Nucl Med, 46, 1959

Maeda, 2007, Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography, J Neurosci, 27, 10957, 10.1523/JNEUROSCI.0673-07.2007

Masters, 1985, Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels, EMBO J, 4, 2757, 10.1002/j.1460-2075.1985.tb04000.x

Mathis, 2002, A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain, Bioorg Med Chem Lett, 12, 295, 10.1016/S0960-894X(01)00734-X

Mathis, 2005, Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies, Arch Neurol, 62, 196, 10.1001/archneur.62.2.196

Mathis, 2003, Synthesis and evaluation of 11C-labeled 6-substituted 2-aryl benzothiazoles as amyloid imaging agents, J Med Chem, 46, 2740, 10.1021/jm030026b

Mathis, 2004, Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain, Curr Pharma Design, 10, 1469, 10.2174/1381612043384772

Mayeux, 1998, Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease, N Engl J Med, 338, 506, 10.1056/NEJM199802193380804

McKhann, 1984, Clinical diagnosis of Alzheimer's disease: Report of Health and Human Services Task Force on Alzheimer's Disease, Neurology, 34, 939, 10.1212/WNL.34.7.939

Meltzer, 1999, Comparative evaluation of MR-based partial-volume correction schemes for PET, J Nucl Med, 40, 2053

Mena, 1996, Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer's disease, Acta Neuropathol (Berl), 91, 633, 10.1007/s004010050477

Mena, 1995, Monitoring pathological assembly of tau and beta-amyloid proteins in Alzheimer's disease, Acta Neuropathol, 89, 50, 10.1007/BF00294259

Mercken, 1992, Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes, Acta Neuropathol, 84, 265, 10.1007/BF00227819

Mintun, 1984, A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography, Ann Neurol, 15, 217, 10.1002/ana.410150302

Mirra, 1991, The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease, Neurology, 41, 479, 10.1212/WNL.41.4.479

Morris, 2005, Role of biomarkers in studies of presymptomatic Alzheimer's disease, Alzheimer Dem, 1, 145, 10.1016/j.jalz.2005.09.013

Naslund, 2000, Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline, JAMA, 283, 1571, 10.1001/jama.283.12.1571

Nicoll, 2006, Abeta species removal after abeta42 immunization, J Neuropathol Exp Neurol, 65, 1040, 10.1097/01.jnen.0000240466.10758.ce

Pearl, 1997, Diagnosis of Alzheimer's disease in a community hospital-based brain bank program, South Med J, 90, 720, 10.1097/00007611-199707000-00013

Perry, 1993, Immunocytochemical evidence that the beta-protein precursor is an integral component of neurofibrillary tangles of Alzheimers Disease, Am J Pathol, 143, 1586

Price, 2005, Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B, J Cereb Blood Flow Metab, 25, 1528, 10.1038/sj.jcbfm.9600146

Rowe, 2007, Imaging beta-amyloid burden in aging and dementia, Neurology, 68, 1718, 10.1212/01.wnl.0000261919.22630.ea

Russo, 2002, Pyroglutamate-modified amyloid beta-peptides–AbetaN3(pE)–strongly affect cultured neuron and astrocyte survival, J Neurochem, 82, 1480, 10.1046/j.1471-4159.2002.01107.x

Small, 2006, PET of brain amyloid and tau in mild cognitive impairment, N Engl J Med, 355, 2652, 10.1056/NEJMoa054625

Spillantini, 1990, Topographical relationship between beta-amyloid and tau protein epitopes in tangle-bearing cells in Alzheimer disease, Proc Natl Acad Sci USA, 87, 3952, 10.1073/pnas.87.10.3952

Tabaton, 1991, Ultrastructural localization of beta-amyloid, tau, and ubiquitin epitopes in extracellular neurofibrillary tangles, Proc Natl Acad Sci USA, 88, 2098, 10.1073/pnas.88.6.2098

Thal, 2006, The role of biomarkers in clinical trials for Alzheimer disease, Alzheimer Dis Assoc Disord, 20, 6, 10.1097/01.wad.0000191420.61260.a8

Thies, 2007, Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1, J Neurosci, 27, 2896, 10.1523/JNEUROSCI.4674-06.2007

Verga, 1989, Alzheimer patients and Down patients: cerebral preamyloid deposits differ ultrastructurally and histochemically from the amyloid of senile plaques, Neurosci Lett, 105, 294, 10.1016/0304-3940(89)90636-8

Verhoeff, 2004, In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET, Am J Geriatr Psychiatry, 12, 584